224 related articles for article (PubMed ID: 14660997)
21. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
Turley AJ; Roberts AP; Morley R; Thornley AR; Owens WA; de Belder MA
Interact Cardiovasc Thorac Surg; 2008 Apr; 7(2):231-4. PubMed ID: 18234766
[TBL] [Abstract][Full Text] [Related]
22. Interventions to improve guideline compliance following coronary artery bypass grafting.
Yam FK; Akers WS; Ferraris VA; Smith K; Ramaiah C; Camp P; Flynn JD
Surgery; 2006 Oct; 140(4):541-7; discussion 547-52. PubMed ID: 17011901
[TBL] [Abstract][Full Text] [Related]
23. Use of secondary preventive medications after the first attack of acute coronary syndrome.
Salomaa V; Pääkkönen R; Hämäläinen H; Niemi M; Klaukka T
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):386-91. PubMed ID: 17568237
[TBL] [Abstract][Full Text] [Related]
24. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
Eagle KA; Kline-Rogers E; Goodman SG; Gurfinkel EP; Avezum A; Flather MD; Granger CB; Erickson S; White K; Steg PG
Am J Med; 2004 Jul; 117(2):73-81. PubMed ID: 15234641
[TBL] [Abstract][Full Text] [Related]
25. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry.
Danchin N; Cambou JP; Hanania G; Kadri Z; Genès N; Lablanche JM; Blanchard D; Vaur L; Clerson P; Guéret P;
Am Heart J; 2005 Dec; 150(6):1147-53. PubMed ID: 16338251
[TBL] [Abstract][Full Text] [Related]
26. The effect of the UK incentive-based contract on the management of patients with coronary heart disease in primary care.
McGovern MP; Boroujerdi MA; Taylor MW; Williams DJ; Hannaford PC; Lefevre KE; Simpson CR
Fam Pract; 2008 Feb; 25(1):33-9. PubMed ID: 18222938
[TBL] [Abstract][Full Text] [Related]
27. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological interventions to manage coronary heart disease.
Parkinson D
Nurs Times; 2003 Jul 8-14; 99(27):48-9. PubMed ID: 12882058
[TBL] [Abstract][Full Text] [Related]
29. Parabolas of medication use and discontinuation after myocardial infarction--are we closing the treatment gap?
Hudson M; Richard H; Pilote L
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):773-85. PubMed ID: 17486661
[TBL] [Abstract][Full Text] [Related]
30. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
Gasse C; Jacobsen J; Larsen AC; Schmidt EB; Johannesen NL; Videbaek J; Sørensen HT; Johnsen SP
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):51-8. PubMed ID: 17923426
[TBL] [Abstract][Full Text] [Related]
31. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis.
van der Elst ME; Bouvy ML; de Blaey CJ; de Boer A
Clin Ther; 2005 Nov; 27(11):1806-14. PubMed ID: 16368451
[TBL] [Abstract][Full Text] [Related]
32. Patient adherence: the next frontier in quality improvement.
Heidenreich PA
Am J Med; 2004 Jul; 117(2):130-2. PubMed ID: 15234651
[No Abstract] [Full Text] [Related]
33. Acute treatment of myocardial infarction in Canada 1999-2002.
Jackevicius CA; Alter D; Cox J; Daly P; Goodman S; Filate W; Newman A; Tu JV;
Can J Cardiol; 2005 Feb; 21(2):145-52. PubMed ID: 15729413
[TBL] [Abstract][Full Text] [Related]
34. The impact of patient-specific quality-of-care report cards on guideline adherence in heart failure.
Matthews JC; Johnson ML; Koelling TM
Am Heart J; 2007 Dec; 154(6):1174-83. PubMed ID: 18035092
[TBL] [Abstract][Full Text] [Related]
35. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project.
Niu S; Zhao D; Zhu J; Liu J; Liu Q; Liu J; Wang W; Smith SC;
Am Heart J; 2009 Apr; 157(4):709-15.e1. PubMed ID: 19332200
[TBL] [Abstract][Full Text] [Related]
36. Predictors of long-term use of evidence-based therapies after non-ST-segment elevation acute coronary syndrome. The S-Témoin survey.
Danchin N; Diévart F; Thébaut JF; Grenier O; Mihci E; Herrmann MA; Ferrières J
Int J Cardiol; 2009 Mar; 133(1):32-40. PubMed ID: 18375000
[TBL] [Abstract][Full Text] [Related]
37. Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model.
Kellett J
Eur J Surg; 1997 Jul; 163(7):539-46. PubMed ID: 9248989
[TBL] [Abstract][Full Text] [Related]
38. Changing patterns of secondary preventive medication among newly diagnosed coronary heart disease patients with diabetes in Finland: a register-based study.
Vehko T; Manderbacka K; Arffman M; Sund R; Reunanen A; Keskimäki I
Scand J Public Health; 2010 May; 38(3):317-24. PubMed ID: 20228159
[TBL] [Abstract][Full Text] [Related]
39. [Reasons for the under-use of secondary prevention therapies in coronary patients over the age of 70 years].
Cournot M; Cambou JP; Quentzel S; Danchin N
Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S17-23. PubMed ID: 16411647
[TBL] [Abstract][Full Text] [Related]
40. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
